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Summary
 Aim The aim of this study is to assess the results of postoperative radiochemotherapy 
in pts with rectal cancer, factors inﬂ uencing prognosis with regard to causes of 
failure and treatment tolerance.
 Materials/Methods Between 1993 and 2002, 178 pts with Dukes stage B or C rectal cancer received 
postoperative chemoradiotherapy. Median age was 62; 110 patients were males, 
68 were females. Median follow-up time was 45 months. Sixty-nine patients had 
stage B and 109 had stage C disease. Main endpoints of the analysis were locore-
gional recurrence-free survival (LRRFS), disease-free survival (DFS) and overall 
survival (OS). Kaplan-Meier method was used to calculate survival rates. Univariate 
and multivariate analyses of prognostic factors were performed using log rank 
test and Cox’s proportional hazard method.
 Results The 5-year LRRFS was 73%, DFS was 61% and OS was 65%. Lymph node involve-
ment and method of resection (AR favoured) were the only independent prog-
nostic factors for LRRFS. Lymph node involvement, in particular when four or 
more were involved, was the independent prognostic factor for DFS. For OS, the 
independent prognostic factors were inﬁ ltration of the pararectal fatty tissue, 
lymph node involvement in particular when four or more were involved, and to-
tal number of chemotherapy cycles (at least six favoured). Radiation therapy was 
well tolerated in 45% of patients. The most common early reactions were diar-
rhoea, nausea/vomiting and leucopoenia.
  Neither SER (start of any treatment to the end of radiotherapy) nor total treat-
ment time appeared to be of prognostic signiﬁ cance in this group of patients.
 Conclusions Involvement of lymph nodes and method of resection were the only independ-
ent prognostic factors for LRRFS. Prognostic factors for OS were inﬁ ltration of 
the pararectal fatty tissue, lymph node metastases, four or more involved lymph 
nodes, and total number of chemotherapy cycles.
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BACKGROUND
In Poland there are approximately 4700 new cas-
es of rectal cancer registered each year (2685 in 
males, 2032 in females) and the disease repre-
sents the seventh and eighth most common site 
of cancer among males and females respectively. 
Approximately 1200 males and 1000 females die of 
rectal cancer annually. The treatment of colorec-
tal cancer is now multidisciplinary and guided by 
precise staging and histopathology. Postoperative 
chemoradiotherapy has been the standard man-
agement for stage B and C patients with aden-
ocarcinoma of the rectum with the objective of 
decreasing local recurrence rate and improving 
overall survival, as shown in several randomised 
controlled trials. Results of two randomised con-
trolled trials [1,2] led to a National Institutes of 
Health Consensus Conference recommendation 
that patients with stage B or C rectal cancer should 
be treated with postoperative chemioradiothera-
py [3]. The protocol of postoperative treatment 
of rectal cancer patients, consisting of postopera-
tive adjuvant chemotherapy (6 cycles of 5-FU) and 
radiotherapy according to NCI, was introduced at 
the Centre of Oncology in Kraków in 1992.
AIM
The aim of this paper is an assessment of results 
of adjuvant chemoradiotherapy in patients with 
rectal cancer with respect to prognostic factors, 
causes of treatment failures and treatment tol-
erance.
MATERIALS AND METHODS
Retrospective analysis was performed in a group 
of 178 patients after resection (R0 or R1) of ad-
enocarcinoma of the rectum with Dukes stage B 
or C. All patients had to be older than 18 and 
younger than 80.
All patients received adjuvant chemoradiother-
apy. Characteristics of patients are shown in 
Table 1.
Anterior resection was performed in 93 pts and 
abdominoperineal resection in 85 pts. Only 
30% (50/178) of patients were operated at the 
Institute of Oncology in Kraków; the majority 
of them had undergone resection in surgical 
departments of general hospitals (123/178). 
Abdominoperineal resection was performed 
when rectal cancer was localized proximal to the 
anal verge, so anterior radical resection with cur-
ative intent was impossible to perform. All pa-
tients were referred for postoperative chemora-
diotherapy.
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Characteristics n %
Age
 Median 62
 Range 32–80
Sex
 Female 68 38.0%
 Male 110 62.0%
Stage (Dukes, Astler-Coller)
 B 69 39.0%
 C 109 61.0%
Type of resection
 Abdominoperineal resection 93 52.0%
 Anterior resection 85 48.0%
Completeness of operation
 R0 168 94.3%
 R1 9 5.1%
 R2 1 0.6%
Histological grade
 G1 33 18.5%
 G2 90 50.6%
 G3 6 3.4%
 Not known 49 27.5%
Table 1. Characteristics of patients.
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Patients were treated with two (1st and 2nd cycle) 
initial four-week cycles of infusion of ﬂ uorouracil 
(5-FU) and folinic acid (FA) (5-FU 500 mg per 
square metre, FA 20 mg per square metre; on days 
1 to 5), folinic acid, followed by radiation thera-
py and concomitant FUFA treatment (5-FU 350 
mg per square metre, FA 20mg per square me-
tre; ﬁ rst (3rd cycle) and last three days (4th cycle) 
of radiation), followed by last two four-week cy-
cles of infusion of ﬂ uorouracil (5-FU) and folinic 
acid (FA) (5-FU 500 mg per square metre, FA 20 
mg per square mete; on days 1 to 5) (Figure 1).
Radiation was delivered with 6MV linear accel-
erator or with Cobalt-60 unit. Four-ﬁ eld “box” 
techniques were used to include the tumour bed 
and pelvic nodes (opposed anteroposterior-pos-
teroanterior and opposed lateral ﬁ elds) and 118 
(66%) patients received boost dose to the tumour 
bed using the two-ﬁ eld technique.
More than half of the patients (57%) were treat-
ed strictly according to the protocol. There were 
some protocol violations. Number of chemo-
therapy cycles ranged from 3 to 8 (median 5.8). 
Median time from operation to the end of radi-
otherapy (SER) was 7 months (range 3–11). The 
main reason (25%) for delay was late referral to 
the Centre of Oncology and radiation therapy 
waiting list. Median radiation dose was 5040cGy 
(4500cGy in 25 fraction and boost 540cGy in 3 
fraction). It was impossible to localize the tumour 
bed during radiotherapy planning in a minori-
ty of patients (36%) so they did not receive a ra-
diation boost.
Among 178 patients undergoing postoperative 
irradiation, 1 (0.5%) failed to complete treat-
ment due to side effects of diarrhoea and vomit-
ing. In 33/178 patients (18.5%) time of radiation 
was prolonged to more than 6 weeks. The main 
causes of extension were machine breakdown , 
conservation jobs (16 patients), and other breaks 
in work, e.g. holidays (11 patients).
Statistical methods
Main endpoints of the analysis were locore-
gional recurrence-free survival (LRRFS), dis-
ease-free survival (DFS) and overall survival 
(OS) rates.
Survival was measured from resection to the date 
of death or lost to follow-up. Time to progression 
was measured from the date of resection to the 
date of local or distant progression. Local fail-
ure was deﬁ ned as failure occurring inside the 
pelvis (and/or perineum) and distant failure as 
any site of failure outside the pelvis.
SER was measured from the date of operation to 
the end of radiotherapy.
Kaplan-Meier method was used to calculate sur-
vival rates. Univariate and multivariate analyses of 
prognostic factors were performed using log rank 
and Cox’s proportional hazard method. In the 
course of analyses of prognostic factors clinical 
factors (sex, age, stage, grade, nodal status, etc) 
and treatment factors (method of resection, com-
pleteness, radiation dose, boost, total number of 
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Figure 1. Chemoradiotherapy regiment according to NCI.
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chemotherapy cycles, SER, total treatment time, 
year of start of treatment) were compared.
RESULTS
Survival
After a median follow-up of 45 months (range 
8–144), we observed 53 cancer related deaths, 
15 pts died from other reasons and 110 were 
alive in January 2005 (including 95 disease-free 
patients).
The 5-year LRRFS rate and DFS rate were 73% 
and 61% respectively. The 5-year OS rate was 65% 
(Figure 2). The 5-year OS were 77% for Dukes B 
stage and 57% for Dukes C stage.
In the course of the univariate analysis (Table 2) 
we found that Dukes stage, type of operation, 
SER, and year of start of treatment had a signif-
icant impact on LRRFS.
The following prognostic factors inﬂ uenced DFS: 
Dukes stage, type of operation, extracapsular ex-
tension of the lymph node metastases, inﬁ ltra-
tion of the pararectal fatty tissue, four or more 
involved lymph nodes.
Dukes stage, differentiation of the tumour, inﬁ l-
tration of the pararectal fatty tissue, four or more 
involved lymph nodes, six or more received cy-
cles of chemotherapy were statistically signiﬁ cant 
prognostic factors for OS.
The risk of locoregional recurrence after anterior 
resection was less than half of the risk in patients 
after abdominoperineal resection (Table 3).
In the multivariate analysis, the following prog-
nostic factors had a statistically signiﬁ cant impact 
on recurrence: Dukes C stage, four or more in-
volved lymph nodes, which had more than twice 
as high risk of recurrence compared to, respec-
tively, Dukes B patients and one to three involved 
lymph nodes (Table 4).
For OS (Table 5), the independent prognostic 
factors were inﬁ ltration of the pararectal fatty 
tissue, involvement of lymph nodes, in particu-
lar four or more involved lymph nodes, and to-
tal number of chemotherapy cycles (at least six 
favoured).
Analysis of failure
During follow-up, recurrence of malignancy was 
observed in 65 patients (37%). In 36 (20%) pa-
tients distant failure was observed. In 21 cases 
(58%) distant failure was located in the liver; in 
13 (36%) it was found in the lungs. Median time 
to distant recurrence was 18 months (6–76).
The main cause of failure were locoregional re-
currences (42/178–24%). The most common 
site of locoregional recurrence was the pelvis 
(32/42–76%), perineal region (8/42–19%) and 
pelvic lymph nodes (7/42–17%). Median time to 
local recurrence was 19 months (3–61).
In 13 (7%) patients both distant and locoregion-
al failures were observed.
Treatment tolerance
Treatment was well tolerated by 80 patients 
(45%); 98 (55%) noticed at least one early com-
plication. The most common complications of 
both chemotherapy and radiotherapy were di-
arrhoea (63/178), nausea/vomiting (26/178), 
leucopoenia (13/178), and early skin reactions 
(13/178). There was one serious (grade III/IV) 
side effect: thrombocytopoenia. Severities of the 
reactions are shown in Table 6.
DISCUSSION
Surgery still remains the principle method of treat-
ment of rectal cancer. In 1982 a new technique 
was developed based on adequate en bloc clear-
ance of the rectal mesentery, including its blood 
supply and lymphatic drainage – Total Mesorectal 
Excision (TME). Local recurrence rates following 
TME approximate 6.6% from published series, ac-
counting for more than 5,000 patients [4].
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Figure 2. Overall survival (OS) for all 178 patients.
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Prognostic factors Number of pts. % 5 year LRFS% 5 year DFS% 5 year OS%
Total group 178 100% 73% 61% 65%
Sex
 Female 68 38% 70% 60% 62%
 Male 110 62% 75% 61% 67%
Age
 >60 y. 100 56% 72% 60% 60%
 <60 y. 78 44% 74% 62% 68%
Histological grade
 G1 33 18.5% 68% 50% 66%
 G2 90 50.6% 70% 61% 60%
 G3 6 3.4% 100% 0% 0%p=0.012
 Not known 49 27.5% 79% 72% 75%
Stage (Dukes. Astler-Coller)
 B 68 38% 83% 75% 77%
 C 110 62% 64%p=0.012
53%
p=0.0006
57%
p=0.009
Type of resection
 Anterior resection 93 52% 84% 71% 74%
 Abdominoperineal resection 85 48% 59%p=0.002
51%
p=0.014 55%
Completeness of operation
 R0 168 94% 58% 48% 80%
 R1 9 5.5% 74% 62% 64%
 R2 1 0.5%
Tumour invasion through rectal wall
 whole 172 97% 72% 60% 63%
 partial 6 3% 83% 83% 100%
Infi ltration of the pararectal fatty tissue
 yes 128 72% 69% 57% 60%
 no 50 28% 81% 70%p=0.049
76%
p=0.001
Number of involved lymph nodes
 0 68 38.2% 77%
 1–3 76 42.7% 69% 60% 68%
 ≥4 34 19.1% 57% 35%p=0.023
32%
p=0.0012
Extracapsular extension of the lymph node metastases
 no 160 90% 75% 64% 66%
 yes 18 10% 54% 35% p=0.007
48% 
p=0.051
Table 2. Univariate analysis of prognostic factors (signifi cant bolded).
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Variable Relative risk P-value
Anterior resection vs 
abdominoperineal resection 0.4 0.007
Dukes C vs Dukes B 2.15 0.036
Table 3. 5 years multivariate analysis of prognostic factors for LRFS.
Variable Relative risk P-value
Dukes C vs Dukes B 2.58 0.001
Four or more vs less than four 
involved lymph nodes 2.03 0.02
Table 4. 5 years multivariate analysis of prognostic factors for DFS.
Variable Relative risk P-value
Dukes C vs Dukes B 1.87 0.024
Four or more vs less than four 
involved lymph nodes 2.23 0.006
Infi ltration of the pararectal 
fatty tissue vs no infi ltration 2.54 0.007
Total number of chemotherapy 
cycles (six and more vs less 
than six)
0.51 0.015
Table 5. 5 years multivariate analysis of prognostic factors for OS.
Complication
EORTC/RTOG scale
I II III/IV
Diarrhoea 45 19 0
Nausea/vomiting 20 6 0
Leucopoenia 9 4 0
Early skin reaction 6 7 0
Thrombocytopoenia 1 0 1
Table 6. Treatment early complications (number of patients).
* 4 year survival.
Prognostic factors Number of pts. % 5 year LRFS% 5 year DFS% 5 year OS%
Total number of chemotherapy cycles
 1–5 38 21.3% 66% 52% 47%
 ≥6 140 78.6% 74% 63% 69%p=0.047
Total treatment time (months)
 Less than 6.5 85 47.8% 70 61% 63%
 More than 6.5 93 52.2% 72% 61% 66%
SER (months)
 <5 60 33.7% 63% 56% 65%
 ≥5 118 66.3% 78%p=0.03 64% 64%
Year of start of treatment
 1992–2000 128 72% 72.7%* 78%* 61%
 2001–2002 50 28% 88.4%*p=0.046 61%%* 78%
Radiation dose
 <4600 33 19% 83% 71% 66%
 ≥4600 145 81% 71% 60% 64%
Radiation boost
 yes 118 66% 69% 66% 61%
 no 60 36% 78% 70% 71%
Table 2. Continued. Univariate analysis of prognostic factors (signifi cant bolded).
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The protocol of postoperative treatment of B and 
C stage rectal cancer according to NCI was intro-
duced in the Centre of Oncology in Kraków in 
1992. It was known (GITS [1] and Mayo/NCCTG 
[2]) that surgery and postoperative combined 
modality treatment (radiochemotherapy) had 
reduced local recurrence rates and improved 
overall survival compared with surgery alone or 
surgery with postoperative radiotherapy. Both 
earlier trials were randomised. In GITS (227 pa-
tients) there was a signiﬁ cant improvement in 
survival in patients who received postoperative 
chemoradiotherapy compared with the surgery-
alone control arm (54% vs. 27%, p=0.005). In the 
Mayo/ NCCTG trial (204 participants) patients 
who received postoperative chemoradiotherapy 
had a signiﬁ cant decrease in local failure (14% 
vs. 25%, p=0.036), distant failure (29% vs. 46%, 
p=0.011) and an increase in 5-year disease-free 
survival (63% vs. 42%, p=0.0016) and overall sur-
vival (57% vs. 48%, p=0.025) compared with post-
operative radiotherapy alone. Later trials also 
showed that postoperative chemoradiotherapy 
reduces local failure rate and improves overall 
survival compared with surgery alone and reduc-
es local failure rate compared with postoperative 
chemotherapy alone [5,6]. Moreover, Intergroup 
86-47-51 trial has demonstrated a 10% improved 
overall survival with the use of continuous-infu-
sion 5-FU during the course of radiation therapy 
compared with bolus 5-FU [7]. Our results show 
comparable overall and disease-free survival to 
Tveit trial [5] results.
Local failure rates after postoperative radio-
therapy in the reported studies were between 
11 and 21%. Our result – 24% were evaluated 
by dividing locoregional failure observed and 
the total number of patients. Moreover, loco-
regional failure rate is higher than distant fail-
ure rate (20%). Our surprising results could be 
caused by the fact that TME (Total Mesorectal 
Excision) was introduced to the hospitals in the 
late nineties.
Involvement of lymph nodes was an independent 
prognostic factor for LRRFS, DFS and OS [8]. It 
is well known that patients with positive lymph 
nodes (especially more than 4) have higher both 
distant and local failure rates [9].
Also the method of resection (favouring AR) 
(which is also an independent prognostic factor 
in our series) can signiﬁ cantly affect outcome 
[10,11]. The poor prognosis of patients with an 
APR is ascribed to the resection plane of the op-
eration leading to a higher frequency of margin 
involvement by the tumour and perforation with 
this surgical technique.
Patients who started treatment later than in 2000 
have fewer recurrences than those treated earlier 
(univariate analysis). That could be explained by 
the fact of improvement of training of the staff 
in the use of medical (especially surgical) tech-
nologies (learning curve).
Neither SER (start of any treatment and the end 
of radiotherapy as deﬁ ned by Bentzen) nor total 
treatment time appeared to be of prognostic sig-
niﬁ cance in this group of patients. A trial which 
compared the use of “early” radiotherapy (con-
comitantly with 1st and 2nd cycle of chemothera-
py) with “late” radiotherapy (concomitantly with 
3rd and 4th cycle of chemotherapy) showed signif-
icantly prolonged DFS [10] in the “early” radio-
therapy group. In our series, patients ended ra-
diotherapy later than in that trial, which could 
have worsened the results.
We also reported paradoxical results, which were 
not conﬁ rmed in multivariate analysis: LRFS and 
DFS were better in patients who received less 
than 4600cGy or who ﬁ nished radiotherapy lat-
er than 5 months after surgery than respective-
ly in patients who received more than 4600cGy 
or ﬁ nished radiotherapy within 5 months af-
ter surgery. These results, which are not con-
ﬁ rmed in other publications, could be ascribed 
to chance only.
More than half of the total number of patients 
noticed at least one early complication. The fre-
quency of the most common early complications 
of both chemotherapy and radiotherapy, i.e. di-
arrhoea, nausea/vomiting, leucopenia and ear-
ly skin reactions, is lower than in the reported 
trials [1,2,5,6,12].
Since publication of the Swedish Rectal Cancer 
Trial [13], which was the ﬁ rst randomised con-
trolled trial to show survival beneﬁ t for patients 
irradiated preoperatively in comparison with sur-
gery alone, many encouraging results have been 
reported [14]. Neoadjuvant radiotherapy decreas-
es the relative risk of a local failure by 50–70% 
(postoperative by 30–40%) [15]. Nowadays pre-
operative radiotherapy or radiochemotherapy is 
a dominant option in the treatment of Dukes B 
and C rectal cancer. Nevertheless, many patients 
are still referred to radiotherapy/chemotherapy 
departments after surgery.
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